Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepatocellular Carcinoma
NCT07490262Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of IBI310 in hepatocellular carcinoma (HCC), sponsored by Innovent Biologics. Started Mar 2026; status: recruiting.
02
Drugs
IBI310
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07490262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490262.